These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29801053)

  • 21. Nusinersen Use in Spinal Muscular Atrophy.
    Pediatrics; 2019 Jan; 143(1):. PubMed ID: 30584063
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
    Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
    Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
    Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
    J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nusinersen (Spinraza) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):50-52. PubMed ID: 28323809
    [No Abstract]   [Full Text] [Related]  

  • 27. Nusinersen: Evidence of sustained clinical improvement and lessened fatigue in older ambulatory patients with spinal muscular atrophy.
    McMillan HJ
    Muscle Nerve; 2020 Jan; 61(1):1-2. PubMed ID: 31599453
    [No Abstract]   [Full Text] [Related]  

  • 28. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound-guided cervical puncture for nusinersen administration in adolescents.
    Ortiz CB; Kukreja KU; Lotze TE; Chau A
    Pediatr Radiol; 2019 Jan; 49(1):136-140. PubMed ID: 30167764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Takanashi JI; Takase N
    Neurology; 2019 Sep; 93(10):464. PubMed ID: 31477617
    [No Abstract]   [Full Text] [Related]  

  • 31. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
    Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
    Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 33. New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.
    Morrow T
    Manag Care; 2017 Feb; 26(2):36-37. PubMed ID: 28271991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nusinersen in SMA 2 and 3: Risks vs benefits.
    Deymeer F
    Neurology; 2020 Jul; 95(4):151-152. PubMed ID: 32665409
    [No Abstract]   [Full Text] [Related]  

  • 35. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
    Touznik A; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motor neuron disease: Nusinersen potentially effective in SMA.
    Adams L
    Nat Rev Neurol; 2017 Feb; 13(2):66. PubMed ID: 28009016
    [No Abstract]   [Full Text] [Related]  

  • 37. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
    Bielsky AR; Fuhr PG; Parsons JA; Yaster M
    Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor neuron disease: Benefits of nusinersen extend to later-onset SMA.
    Wood H
    Nat Rev Neurol; 2018 Apr; 14(4):196. PubMed ID: 29497154
    [No Abstract]   [Full Text] [Related]  

  • 39. Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy.
    Maharshi V; Hasan S
    Clin Drug Investig; 2017 Sep; 37(9):807-817. PubMed ID: 28755059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience].
    Walter MC; Dräger B; Günther R; Hermann A; Hagenacker T; Kleinschnitz C; Löscher W; Meyer T; Schrank B; Schwersenz I; Wurster CD; Ludolph AC; Kirschner J
    Nervenarzt; 2019 Apr; 90(4):343-351. PubMed ID: 30617569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.